900 related articles for article (PubMed ID: 25029937)
21.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
22. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
23. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
25. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
[TBL] [Abstract][Full Text] [Related]
26. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP
Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056
[TBL] [Abstract][Full Text] [Related]
28. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
[TBL] [Abstract][Full Text] [Related]
29. 177 Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor.
Parghane RV; Basu S
Clin Nucl Med; 2022 Oct; 47(10):874-875. PubMed ID: 35353741
[TBL] [Abstract][Full Text] [Related]
30. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
31. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
32. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
33. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Shamim SA; Kumar A; Kumar R
PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
35. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
[TBL] [Abstract][Full Text] [Related]
36. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
37. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
38. 3p-C-NETA: A versatile and effective chelator for development of Al
Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
[No Abstract] [Full Text] [Related]
39. Nuclear medicine in NET.
Sorschag M; Malle P; Gallowitsch HJ
Wien Med Wochenschr; 2012 Oct; 162(19-20):416-22. PubMed ID: 22810487
[TBL] [Abstract][Full Text] [Related]
40. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT.
Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E
Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
